⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335173 | 0.83 | — | — | |
| SCHEMBL2187023 | 0.65 | — | — | |
| SCHEMBL297724 | 0.62 | — | — | |
| SCHEMBL376443 | 0.61 | AXL (0.38) | — | |
| SCHEMBL3263618 | 0.61 | — | — | |
| SCHEMBL2189583 | 0.60 | CA1 (0.36) | — | |
| SCHEMBL21903125 | 0.60 | HDAC8 (0.32) | — | |
| SCHEMBL11033034 | 0.60 | ALDH1A1 (0.30) | — | |
| SCHEMBL5495169 | 0.60 | SMPD3 (0.37) | — | |
| SCHEMBL6845042 | 0.60 | ATM (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005265-A1 | METHODS AND COMPOSITIONS FOR COMBINATION THERAPY USING P13K/MTOR INHIBITORES | TOKAI PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | claimed |
| EP-2793896-A1 | METHODS AND COMPOSITIONS FOR COMBINATION THERAPY USING P13K/MTOR INHIBITORS | Tokai Pharmaceuticals, Inc. (US) | 2014-10-29 | — | — | EP | claimed |
| WO-2013096907-A1 | METHODS AND COMPOSITIONS FOR COMBINATION THERAPY USING P13K/MTOR INHIBITORS | TOKAI PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | claimed |
| US-20110319369-A1 | COMBINATION OF A 17 ALPHA-HYDROXYLASE/C17, 20-LYASE INHIBITOR WITH AN ADDITIONAL THERAPEUTIC AGENT | TOKAI PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | claimed |
| US-8058425-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-11-15 | — | — | US | claimed |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | claimed |
| WO-2010091299-A2 | NOVEL COMBINATION CANCER THERAPIES | TOKAI PHARMACEUTICALS (US) | 2010-08-12 | — | — | WO | claimed |
| EP-4334319-A1 | 2,8-DIHYDROPYRAZOLO[3,4-B]INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| US-11771088-B2 | Insecticidal compositions and methods | MONSANTO TECHNOLOGY LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| US-11180483-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| WO-2010091299-A2 | NOVEL COMBINATION CANCER THERAPIES | TOKAI PHARMACEUTICALS (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010091303-A1 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS | TOKAI PHARMACEUTICALS (US) | 2010-08-12 | — | — | WO | disclosed |
| EP-2177526-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090076253-A1 | MACROLIDE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1820504-A1 | IMINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-08-22 | — | — | EP | disclosed |